Vincent Brichard

Title: Vincent Brichard: Innovator in Cancer Immunotherapy

Introduction

Vincent Brichard is a notable inventor based in Rixensart, Belgium. He has made significant contributions to the field of cancer immunotherapy through his innovative work on fusion proteins. His research focuses on developing effective vaccine components that can induce immune responses against cancer cells.

Latest Patents

Vincent Brichard holds 1 patent for his invention related to fusion proteins. The patent describes fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1. These proteins may also include carriers, fusion partners, or similar components. The methods for preparing, formulating, and utilizing these fusion proteins are also detailed in the patent. Such proteins are particularly useful as vaccine components for inducing immune responses against a range of cancer-antigen-bearing cells.

Career Highlights

Vincent Brichard is associated with GlaxoSmithKline Biologicals SA, where he continues to advance his research in immunotherapy. His work has been instrumental in developing innovative solutions for cancer treatment, showcasing his commitment to improving patient outcomes.

Collaborations

Vincent collaborates with esteemed colleagues, including Normand Blais and Martine Boyer. Their combined expertise contributes to the ongoing research and development of effective cancer therapies.

Conclusion

Vincent Brichard's contributions to the field of cancer immunotherapy through his innovative work on fusion proteins highlight his role as a key inventor in this critical area of research. His dedication to advancing medical science is evident in his patent and ongoing collaborations.